<DOC>
	<DOCNO>NCT02022540</DOCNO>
	<brief_summary>The objective study assess safety tolerability topical ocular PAN-90806 patient active , subfoveal choroidal neovascularization associate neovascular Age-Related Macular Degeneration ( AMD ) .</brief_summary>
	<brief_title>Phase 1 Study Topical Ocular PAN-90806 Neovascular AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis study eye active , pathologic , newly diagnose previously untreated , subfoveal choroidal neovascular ( CNV ) lesion secondary neovascular AMD Aged 50 year old Demonstrate ability , family member willing able , instill topical ocular drop study eye No prior ocular systemic treatment surgery neovascular AMD study eye History current clinical evidence study eye : aphakia diabetic macular edema ocular inflammation infection pathological myopia retinal detachment advance glaucoma significant medium opacity , include cataract History evidence follow surgery study eye : penetrating keratoplasty vitrectomy ; corneal transplant ; corneal intraocular surgery within 3 month Screening Uncontrolled hypertension despite use antihypertensive medication Participation investigational drug device study , systemic ocular , within past 3 month Women pregnant nursing Known serious allergy hypersensitivity fluorescein dye use angiography component PAN90806 formulation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Neovascular Age-Related Macular Degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>wet AMD</keyword>
	<keyword>neovascular AMD</keyword>
	<keyword>exudative AMD</keyword>
</DOC>